Skip to Content
Merck
  • Terconazole and miconazole cream for treating vulvovaginal candidiasis. A comparison.

Terconazole and miconazole cream for treating vulvovaginal candidiasis. A comparison.

The Journal of reproductive medicine (1991-08-01)
S L Corson, R R Kapikian, R Nehring
ABSTRACT

In a double-blind, randomized, multicenter study, 900 patients diagnosed with vulvovaginal candidiasis received either 0.4% (307 patients) or 0.8% (299 patients) terconazole cream or 2.0% miconazole nitrate cream (294 patients). After seven days of treatment the combined microbiologic and clinical cure rates were 87.9% for the 0.4% terconazole group, 83.8% for patients treated with 0.8% terconazole and 81.3% for the 2.0% miconazole nitrate group. The microbiologic and clinical cure rates were similarly high. The 0.4% terconazole formulation consistently provided a greater degree of symptom relief and significantly fewer adverse genital-reproductive reactions as compared with 2.0% miconazole nitrate. All three preparations were well tolerated, with only minor adverse reactions; all three seem to be useful for the treatment of vulvovaginal candidiasis.

MATERIALS
Product Number
Brand
Product Description

USP
Terconazole, United States Pharmacopeia (USP) Reference Standard
Terconazole, European Pharmacopoeia (EP) Reference Standard
Supelco
Terconazole, VETRANAL®, analytical standard